IDiyas

For the Inventor, By the Inventor

Lansdale, PA, United States of America

Steven M Pitzenberger

USPTO Granted Patents = 12

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 108(Granted Patents)


Company Filing History:

goldMedal12 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1986-1995

Loading Chart...
12 patents (USPTO):Explore Patents
1. 5387512 - Preparation of (1995-02-07),
2. 5288725 - Pyrroloquinoline Bradykinin antagonist (1994-02-22),
3. 5188950 - Method of preparing HIV protease inhibitors (1993-02-23),
4. 4943588 - Prodrugs of antihypercholesterolemic compounds (1990-07-24),
5. 4939139 - 7-chloro-5,6-di (1990-07-03),
6. 4904654 - 7-chloro-5,6-dihydro-3-(5-(2-hydroxy-isoprop (1990-02-27),
7. 4837205 - Prodrugs of antihypercholesterolemic compounds (1989-06-06),
8. 4780538 - Process for 1,4-dihydropyridine compounds using a titanamine catalyst (1988-10-25),
9. 4678806 - Prodrugs of antihypercholesterolemic compounds (1987-07-07),
10. 4675321 - Substituted pyrimidines useful as calcium channel blockers (1987-06-23),
11. 4594191 - Process for preparing a benzodiazepinedione derivative (1986-06-10),
12. 4576750 - Tryptophan derivative (1986-03-18),

Title: The Innovative Contributions of Steven M Pitzenberger

Introduction

Steven M Pitzenberger is a notable inventor based in Lansdale, PA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that have potential therapeutic applications. With a total of 12 patents to his name, Pitzenberger's work is recognized for its impact on medical science.

Latest Patents

Among his latest patents, one notable invention involves the preparation of a compound through the incubation of a specific mammalian organ preparation. This biotransformation product, identified as 3-[2-(benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone, is particularly useful in the prevention or treatment of HIV infections and AIDS. Another significant patent is related to a pyrroloquinoline bradykinin antagonist, which is a compound designed to target specific biological pathways.

Career Highlights

Pitzenberger's career is marked by his association with Merck & Company, Inc., a leading pharmaceutical company. His work there has allowed him to focus on innovative solutions that address critical health issues. His research has contributed to advancements in drug development and therapeutic strategies.

Collaborations

Throughout his career, Pitzenberger has collaborated with esteemed colleagues, including Harri G Ramjit and Wasyl Halczenko. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Steven M Pitzenberger's contributions to the field of biochemistry and his innovative patents highlight his commitment to advancing medical science. His work continues to pave the way for new treatments and therapies that can significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…